Audience Q&A | Unlocking The Potential Of iPSC Therapies In Regenerative Medicine

During this final segment of Cell & Gene Live, our expert panelists, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas, answered audience questions pertaining to the unique challenges facing iPSC, such as managing off-target effects, ensuring safety of master cell banks intended for large patient populations, and addressing product heterogeneity due to residual pluripotent cells or partially differentiated progenitors.